Literature DB >> 23368420

Psychosocial variables are related to future exacerbation risk and perinatal outcomes in pregnant women with asthma.

Heather Powell1, Kirsten McCaffery, Vanessa E Murphy, Michael J Hensley, Vicki L Clifton, Warwick Giles, Peter G Gibson.   

Abstract

OBJECTIVE: To determine the relationship between psychosocial variables, future exacerbation risk during pregnancy, and perinatal outcomes.
METHODS: A secondary analysis of a randomized controlled trial of exhaled nitric oxide versus guideline-based treatment adjustment in pregnant women with asthma. Women were recruited between 12 and 20 weeks gestation and monitored for the remainder of the pregnancy. Psychosocial questionnaires including the Perceived Control of Asthma Questionnaire, the Brief Illness Perception Questionnaire, and the Six-Item Short-Form State Trait Anxiety Inventory were assessed at randomization. Exacerbations were defined as hospitalization, emergency visit, unscheduled doctor visit, or oral corticosteroid use for worsening asthma. Perinatal outcomes included preterm birth, small for gestational age, and cesarean section. Multiple logistic regressions were performed with predictor variables, including demographics and psychosocial and clinical variables.
RESULTS: The 175 participants had a mean (SD) age = 28.5(5.4) years, forced expiratory volume in 1 second (FEV(1)%) predicted = 95.9(13.4), and asthma control score = 0.88(0.70). Greater perceived control of asthma reduced the odds of subsequent exacerbation (odds ratio (OR) [95%CI] 0.92 [0.85, 0.98], p = .016), cesarean without labor (0.84 [0.75, 0.94], p = .003), and preterm birth (0.84 [0.72, 0.97], p = .019), while increased anxiety increased the odds of subsequent exacerbation (1.05 [1.01, 1.08], p = .008).
CONCLUSION: Women's perceptions of asthma control and their psychosocial state (anxiety) are related to future exacerbation risk, cesarean section, and preterm birth.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23368420     DOI: 10.3109/02770903.2012.757777

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  7 in total

Review 1.  Interventions for managing asthma in pregnancy.

Authors:  Emily Bain; Kristen L Pierides; Vicki L Clifton; Nicolette A Hodyl; Michael J Stark; Caroline A Crowther; Philippa Middleton
Journal:  Cochrane Database Syst Rev       Date:  2014-10-21

2.  Risk factors for asthma exacerbation during pregnancy: protocol for a systematic review and meta-analysis.

Authors:  Marleen P Bokern; Annelies L Robijn; Megan E Jensen; Daniel Barker; Katherine J Baines; Vanessa E Murphy
Journal:  Syst Rev       Date:  2022-06-07

3.  Co-morbid psychological dysfunction is associated with a higher risk of asthma exacerbations: a systematic review and meta-analysis.

Authors:  Li Zhang; Xin Zhang; Jing Zheng; Lan Wang; Hong-Ping Zhang; Lei Wang; Gang Wang
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

4.  Investigating Women's Experiences of Asthma Care in Pregnancy: A Qualitative Study.

Authors:  Chervonne Chamberlain; Graham R Williamson; Beatrice Knight; Mark Daly; David M G Halpin
Journal:  Open Nurs J       Date:  2014-12-11

5.  Trajectories of anxiety and health related quality of life during pregnancy.

Authors:  K Oliver Schubert; Tracy Air; Scott R Clark; Luke E Grzeskowiak; Edward Miller; Gustaaf A Dekker; Bernhard T Baune; Vicki L Clifton
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

Review 6.  The effectiveness of non-pharmacological healthcare interventions for asthma management during pregnancy: a systematic review.

Authors:  Elida Zairina; Kay Stewart; Michael J Abramson; Johnson George
Journal:  BMC Pulm Med       Date:  2014-03-19       Impact factor: 3.317

Review 7.  Prenatal Maternal Anxiety as a Risk Factor for Preterm Birth and the Effects of Heterogeneity on This Relationship: A Systematic Review and Meta-Analysis.

Authors:  M Sarah Rose; Gianella Pana; Shahirose Premji
Journal:  Biomed Res Int       Date:  2016-05-19       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.